“Amicable Agreement”
This article was originally published in The Gray Sheet
Executive Summary
Regardless of any positives or negatives associated with the protracted CEO transition at Boston Scientific, one primary driver for the arrangement appears to be an agreement hashed out between the company and Johnson & Johnson allowing Mahoney to make the move in the near term without flouting non-compete requirements for former J&J executives.